Skip to content
Review Open access

Human Herpesvirus 8 Causes a Wide Spectrum of Disease in Liver Transplant Recipients and May be Donor Derived: Case Series and Systematic Review of an Emerging Challenge

Aug 2026 · Transplant Infectious Disease · Vol 28 · 0 citations · 59 references
Medicine

TL;DR

Post‐LT HHV8 disease is heterogeneous, with high mortality, and targeted treatments and possibly donor screening improve survival, which diverged by KS and non‐KS disease.

Abstract

ABSTRACT Background Human herpesvirus 8 (HHV8), also known as Kaposi sarcoma (KS)‐associated herpesvirus, can cause severe disease in liver transplant (LT) recipients, be donor‐derived, and present variably. We describe HHV8 disease post‐LT. Methods HHV8 disease was identified post‐LT in New South Wales (NSW), 2017–2024, and from systematic review. Reports were compared by suspected donor‐derived infection (DDI) and disease manifestation, using chi‐square and t‐tests. Survival was investigated with Cox proportional hazards. Results Of 188 records, 79 publications (131 cases) were included, plus four NSW cases (n = 135). Median onset was 7 months posttransplant (IQR: 5–13), with 33% suspected DDI. After median 12 months of follow‐up, 68/125 had disease remission/regression; 59/135 died (49 HHV8‐related). In NSW, Case 1 was proven DDI: visceral KS, 6 months post‐LT; complete remission occurred with immunosuppression modification and chemotherapy. Case 2 was probable DDI: KS, multicentric Castleman's disease, and hemophagocytic lymphohistiocytosis, 3 months post‐LT; the patient died despite immunosuppression modification, hydrocortisone and rituximab. Case 3 was possible DDI: KS‐herpesvirus‐induced cytokine syndrome, 6 months post‐LT; died despite immunosuppression modification and ganciclovir. Case 4 was unlikely DDI: visceral KS, 5 months post‐LT; complete remission occurred with surgery and immunosuppression modification. Survival was worse with visceral KS and non‐KS disease (aHR 5.83 and 4.32, p = 0.002). Reduced immunosuppression, mTORi, and chemotherapy improved survival (aHRs 0.53, 0.36, 0.43; p = 0.006, 0.044, and 0.030). Treatment effects diverged by KS and non‐KS disease. Donor screening identified more KICS and DDI, with improved non‐KS disease survival. Conclusion Post‐LT HHV8 disease is heterogeneous, with high mortality. Targeted treatments and possibly donor screening improve survival.

Read PDF

Similar papers

Review Aug 2026

Post-transplant Epstein-Barr virus-associated lymphoproliferative disorder after cardiac transplantation: a scoping review.

BACKGROUND Post-transplant lymphoproliferative disorder (PTLD) is a serious complication following cardiac transplantation, frequently driven by Epstein-Barr virus (EBV) in the setting of chronic immunosuppression. Despite its clinical significance, data specific to adult cardiac transplant recipients remain fragmented...

Jacob Calpey, Ryan Beaton, Sofia Valencia Osorio et al. · 0 citations
Review Open access Oct 2026

Epidemiology and Management of Human Herpesvirus 8-Related Diseases in People Living with Human Immunodeficiency Virus in Central and Eastern Europe

Human herpesvirus 8 (HHV-8) is associated with Kaposi sarcoma (KS), multicentric Castleman disease (MCD), and primary effusion lymphoma (PEL), important causes of morbidity among people living with HIV. Data on these diseases remain limited from Central and Eastern Europe compared with Western Europe. We conducted a mu...

Botond Lakatos, Emily Burzynski, Janah Bou Chahine et al. · 0 citations
Review Open access Aug 2026

Multidrug-resistant donor-derived infections in solid organ transplantation: a systematic review and meta-analysis of transmission risk factors.

PURPOSE Donor-derived infections (DDIs) caused by multidrug-resistant organisms (MDROs) are rare but potentially devastating complications of solid organ transplantation (SOT), with limited evidence on transmission risk and clinical outcomes. METHODS We conducted a systematic review in accordance with PRISMA 2020 gui...

Carolina Andrade Lopes, Julia Ferreira Mari, E. Abdala et al. · 0 citations
Review Open access Jan 2026

Belatacept and the Risk of Cytomegalovirus, BK Polyomavirus, and Epstein–Barr Virus Post‐transplant Lymphoproliferative Disease After Kidney Transplantation: A Meta‐Analysis and Systematic Review

Background The long‐term risk of cytomegalovirus (CMV), Epstein–Barr virus (EBV)‐associated post‐transplant lymphoproliferative disorder (PTLD), and BK viral infections from belatacept is unclear. This review aimed to evaluate these outcomes. Methods Several databases were reviewed from inception through September 2025...

C. Abad, R. Razonable · 0 citations
Case report Open access Sep 2026

Adult Epstein–Barr virus encephalitis: a retrospective case report series with metagenomic next-generation sequencing-based diagnosis

Background EBV encephalitis is uncommon in adults, and its diagnosis and management remain challenging, particularly in patients with underlying medical conditions. Methods We retrospectively analyzed seven adult patients with EBV encephalitis confirmed through cerebrospinal fluid (CSF) metagenomic next-generation sequ...

Ying-Hui Li, Zhe-Jun Yu, Mei-Li Shen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.